Atara Biotherapeutics (ATRA) Interest Coverage Ratio (2022 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Interest Coverage Ratio came in at 24.71 in Q2 2026, down 851.33% on a YoY basis from 3.29 in Q2 2025, and down 508.82% quarter-over-quarter from 4.06 in Q1 2026.
Powered by 
Analysis
Atara Biotherapeutics (ATRA) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has reported Interest Coverage Ratio for 5 consecutive years, with 24.71 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio fell 851.33% year-over-year to 24.71; the trailing twelve-month figure through Jun 2026 stood at 5.04 (down 362.5% YoY), and the FY2025 full-year result was 9.46, up 152.31% from the prior year.
- Interest Coverage Ratio fell to 24.71 in Q2 2026 per ATRA's latest filing, from 4.06 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 38.15 in Q1 2025 and bottomed at 22055.0 in Q1 2022.
- Historically, Interest Coverage Ratio has averaged 1328.48 across 5 years, with a median of 25.91 in 2024.
- The sharpest annual moves came in 2025 and 2026: Interest Coverage Ratio jumped 240.78% in 2025, then plunged 851.33% in 2026.
- Over 5 years, Interest Coverage Ratio stood at 645.63 in 2022, then surged by 92.1% to 50.99 in 2023, then surged by 76.47% to 12.0 in 2024, then jumped by 76.11% to 2.87 in 2025, then slumped by 761.98% to 24.71 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 24.71, 4.06, and 2.87 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | -0.01 |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 9.95 |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -3.63 |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 7.67 |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 2.71 |
| 10 | Atara Biotherapeutics | 148.00 Mn | 131.45 Mn | 439,000.00 | -24.71 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.71 |
| Mar 31, 2026 | -4.06 |
| Dec 31, 2025 | -2.87 |
| Sep 30, 2025 | -3.93 |
| Jun 30, 2025 | 3.29 |
| Mar 31, 2025 | 38.15 |
| Dec 31, 2024 | -12.00 |
| Sep 30, 2024 | -18.39 |
| Jun 30, 2024 | -14.45 |
| Mar 31, 2024 | -27.10 |
| Dec 31, 2023 | -50.99 |
| Sep 30, 2023 | -49.90 |
| Jun 30, 2023 | -51.82 |
| Mar 31, 2023 | -56.15 |
| Dec 31, 2022 | -645.63 |
| Sep 30, 2022 | -687.98 |
| Jun 30, 2022 | -249.09 |
| Mar 31, 2022 | -22,055.00 |